Dayvigo is a prescription medication used to treat insomnia characterized by difficulties with sleep onset and/or sleep maintenance [1]. It is a dual-acting orexin receptor antagonist, meaning it works by blocking the activity of orexin, a neurotransmitter that promotes wakefulness [1][2]. By inhibiting orexin signaling, Dayvigo helps to reduce the drive for wakefulness, facilitating sleep [2].
How does Dayvigo work?
Dayvigo contains the active ingredient lemborexant. Lemborexant binds to two types of orexin receptors: orexin 1 (OX1R) and orexin 2 (OX2R) receptors [1][2]. Orexin A and orexin B are neuropeptides that bind to these receptors and are crucial for regulating the sleep-wake cycle. In individuals with insomnia, orexin signaling may be overactive, contributing to difficulty falling asleep or staying asleep. Dayvigo's action as an antagonist at both OX1R and OX2R receptors is believed to reduce the overall excitatory signaling of the orexin system, thereby promoting sleep [2].
What are the different strengths of Dayvigo?
Dayvigo is available in two dosage strengths: 5 mg and 10 mg [1]. The appropriate dose is determined by a healthcare professional based on individual patient needs and response [1].
What are the common side effects of Dayvigo?
Common side effects associated with Dayvigo use include sleepiness or drowsiness, headache, and fatigue [1]. It is important for patients to be aware of these potential side effects and to discuss any concerns with their doctor.
When should Dayvigo not be taken?
Dayvigo should not be taken by individuals with narcolepsy [1]. Additionally, due to its sedative effects, patients should avoid driving or operating heavy machinery until they are sure they can do so safely after taking Dayvigo [1].
What is the difference between Dayvigo and other sleep medications?
Dayvigo is a dual-acting orexin receptor antagonist, distinguishing it from other classes of sleep medications such as benzodiazepines, non-benzodiazepine hypnotics (e.g., zolpidem), or sedating antidepressants [2][3]. Older sleep medications often work by enhancing the effects of GABA, a neurotransmitter that inhibits brain activity, leading to sedation. Orexin receptor antagonists, like Dayvigo, target a different pathway involved in wakefulness [2].
When did Dayvigo become available?
Dayvigo was approved by the U.S. Food and Drug Administration (FDA) in December 2019 [4].
What is the patent status of Dayvigo?
Information regarding the patent status and expiry dates for Dayvigo, including any related intellectual property and potential generic competition, can be found on DrugPatentWatch.com [5].
Sources:
[1] https://www.dayvigo.com/
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151633/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042485/
[4] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-and-releas
[5] https://drugpatentwatch.com/